美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

SPDR S&P Biotech ETF

153.56

-0.4700-0.31%

成交量：734.79萬

成交額：11.37億

市值：104.69億

市盈率：8.42

高：156.04

開：154.58

低：152.50

收：154.03

52周最高：169.89

52周最低：93.26

股本：6,817.50萬

流通股本：6,817.50萬

量比：0.93

換手率：10.78%

股息：0.57

股息率：0.37%

每股收益(TTM):18.23

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

人民健康保險銅川分公司被罰9.9萬，涉虛掛中介業務套取費用

福建：擬支持海峽兩岸生物技術和醫療健康產業合作區建設

福建：擬支持海峽兩岸生物技術和醫療健康產業合作區建設

醫療保健板塊市場動態綜述

據知情人士透露，特朗普政府計劃於周一宣佈與數家中型生物科技公司達成新一輪「最惠國待遇」藥品定價協議。相關公司將同意向各州

醫療板塊市場快訊：行業動態與個股分析

市場消息：白宮將宣佈與多家生物科技企業達成最惠國待遇藥品定價協議。

江蘇：鼓勵商業健康保險、醫療互助等將創新藥納入保障範圍

江蘇：鼓勵生物醫藥企業圍繞新產品研發、新技術應用、新業務佈局等積極增資擴產

江蘇：鼓勵生物醫藥企業圍繞新產品研發、新技術應用、新業務佈局等積極增資擴產

江蘇：發揮省戰新母基金引導作用，支持生物醫藥產業專項母基金直投創新藥械項目

江蘇：推進「人工智能+醫療健康」行動

江蘇：到2028年全省生物醫藥產業規模、創新藥械數量保持全國領先

醫療板塊市場快訊：行業動態一覽

巴克萊(BCS.US)任命Ramin Naji為亞太區醫療健康與房地產業務主管

艾瑋得生物宣佈完成新一輪融資

港股早評：三大指數高開，科網股普漲，生物醫藥股漲幅明顯

港股生物醫藥股大漲，康希諾生物漲逾18%

醫療健康板塊市場綜述：市場快訊

派格生物醫藥-B(02565)發布中期業績研發開支1.1億元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/XBI/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"XBI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","market":"US","secType":"STK","nameCN":"SPDR S&P Biotech ETF","latestPrice":153.56,"timestamp":1789587813836,"preClose":154.03,"halted":0,"volume":7347855,"delay":0,"changeRate":-0.0030513536324092635,"floatShares":68175000,"shares":68175000,"eps":18.23,"marketStatus":"交易中","change":-0.47,"latestTime":"09-16 15:43:35 EDT","open":154.5791,"high":156.04,"low":152.5002,"amount":1136835363.32865,"amplitude":0.022981,"askPrice":153.58,"askSize":390,"bidPrice":153.53,"bidSize":82,"shortable":3,"etf":1,"ttmEps":18.23,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":154.03,"sharesOutstanding":63325000,"nav":157.586874,"aum":10743485169.21,"dividendRate":0.003711,"bidAskSpread":0.000306,"preHourTrading":{"tag":"盘前","latestPrice":155.02,"preClose":154.03,"latestTime":"09:29 EDT","volume":7820,"amount":1209968.8936,"timestamp":1789565346872,"change":0.99,"changeRate":0.006427,"amplitude":0.006817},"postHourTrading":{"tag":"盘后","latestPrice":154.1,"preClose":154.03,"latestTime":"19:59 EDT","volume":217310,"amount":33483251.403,"timestamp":1789516796776,"change":0.07,"changeRate":0.000454,"amplitude":0.001883},"volumeRatio":0.932398,"optionData":{"bulkOrders":[{"symbol":"XBI","call":true,"expireDate":1797570000000,"strike":"170.0","timestamp":1789576413951,"price":4.35,"volume":2000,"amount":870000,"type":"*"}]},"impliedVol":0.3201,"impliedVolPercentile":0.6335},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XBI\",,,,,undefined,":{"symbol":"XBI","floatShares":68175000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.932398,"shares":68175000,"dividePrice":0.5699,"high":156.04,"amplitude":0.022981,"preClose":154.03,"low":152.5002,"week52Low":93.26,"pbRate":"--","week52High":169.89,"institutionHeld":0.8511,"latestPrice":153.56,"committee":0.462069,"eps":18.23,"divideRate":0.003711,"volume":7347855,"delay":0,"ttmEps":18.23,"open":154.5791,"prevYearClose":121.93,"prevWeekClose":156.2,"prevMonthClose":162.5,"prevQuarterClose":158.25,"fiveDayClose":159.38,"twentyDayClose":160.11,"sixtyDayClose":145.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XBI\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"XBI","amount":0.138094,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-24","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-24"},{"date":"2025-12-22","symbol":"XBI","amount":0.406564,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XBI","amount":0.02665,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"},{"date":"2025-06-23","symbol":"XBI","amount":0.007295,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-25"},{"date":"2025-03-24","symbol":"XBI","amount":0.00525,"announcedDate":"2025-03-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-24","defaultRemindTime":1742823000000,"name":"SPDR S&P Biotech ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-26","payableDate":"2025-03-24","currency":"USD","dateTimestamp":1742788800000,"payDate":"2025-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XBI\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-26","value":0.031139,"currency":"USD"},{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.01831,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.019702,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.110135,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-25","value":0.03704,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XBI\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XBI\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662775745","title":"人民健康保險銅川分公司被罰9.9萬，涉虛掛中介業務套取費用","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775745","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662775745?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:56","pubTimestamp":1787813815,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月27日讯，近日，铜川金融监管分局发布行政处罚决定书，剑指中国人民健康保险股份有限公司铜川分公司及相关责任人。罚单显示，中国人民健康保险股份有限公司铜川分公司的主要违法违规行为是：利用保险代理人虚挂中介业务套取费用。针对上述违法行为，铜川金融监管分局对中国人民健康保险股份有限公司铜川分公司罚款9.9万元；对宋鹏飞给予警告并处罚款1.1万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787810487255386596","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["XBI","LABU","XLV","BK4588","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775292","title":"福建：擬支持海峽兩岸生物技術和醫療健康產業合作區建設","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775292","media":"格隆汇APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662775292?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:49","pubTimestamp":1787813340,"startTime":"0","endTime":"0","summary":"格隆汇8月27日丨今日，《福建省“十五五”卫生健康发展规划》印发。其中提到，深化卫生健康两岸融合发展，构建跨区域开放发展新格局。加强两岸医疗健康产业合作，推动闽台在生物医药研发、重大疾病防控、前沿医疗技术研究等领域交流合作。支持海峡两岸生物技术和医疗健康产业合作区建设。深化闽台医药融合，鼓励引进台湾地区已上市的高临床价值创新药械在本省医疗机构应用。支持福建中医药大学建设闽台融合中医药重点实验室。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2026-08-27/doc-inipttav9117970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IXJ","WDNA","VHT","HELX","XLV","BK4588","BK4581","BK4550","159760","XBI","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662077593","title":"福建：擬支持海峽兩岸生物技術和醫療健康產業合作區建設","url":"https://stock-news.laohu8.com/highlight/detail?id=2662077593","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662077593?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 14:45","pubTimestamp":1787813117,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XBI","BK4588","VHT","BK4550","WDNA","XLV","HELX","IXJ","LABU","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171038950","title":"醫療保健板塊市場動態綜述","url":"https://stock-news.laohu8.com/highlight/detail?id=1171038950","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171038950?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 04:53","pubTimestamp":1787777585,"startTime":"0","endTime":"0","summary":"医疗保健领域最新市场快讯，涵盖了多家重要企业的动态与分析师观点。伯恩斯坦研究指出，依视路陆逊梯卡旗下核心品牌雷朋可能因其智能眼镜产品线引发的隐私担忧而遭受长期声誉损害。杰富瑞分析师在一份研究报告中表示，基础医疗控股的长期增长轨迹受到医疗保健使用率上升及其他利好因素的支撑。其门诊设施使其能够从医院护理向门诊护理转移的趋势中获益。杰富瑞首次覆盖该股，给予买入评级，目标价为1.10新加坡元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","BK4581","XLV","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662745971","title":"據知情人士透露，特朗普政府計劃於周一宣佈與數家中型生物科技公司達成新一輪「最惠國待遇」藥品定價協議。相關公司將同意向各州","url":"https://stock-news.laohu8.com/highlight/detail?id=2662745971","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662745971?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 00:37","pubTimestamp":1787762225,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GDOC","BK4581","LNGR","BK4588","MEDX","IEIH","SYNB","HART","IBBJ","AGNG","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175698162","title":"醫療板塊市場快訊：行業動態與個股分析","url":"https://stock-news.laohu8.com/highlight/detail?id=1175698162","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175698162?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 00:24","pubTimestamp":1787761489,"startTime":"0","endTime":"0","summary":"医疗健康板块最新市场快讯，涵盖多家重点企业动态与投资机构观点。0343 ET - 花旗研究维持对药明合联的看涨立场，基于该公司上半年业绩所展现的强劲增长可见性。该股下跌3.6%，报77.30港元。分析师指出，市场热烈反应可能表明部分交易者误将该疫苗理解为预防性治疗，而Moderna可能要到2030年才能实现盈利。Moderna股价上涨14%至158.10美元，过去一个月内市值已近乎翻两番。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","XLV","BK4581","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662745829","title":"市場消息： 白宮將宣佈與多家生物科技企業達成最惠國待遇藥品定價協議。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662745829","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662745829?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 00:14","pubTimestamp":1787760865,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4581","IBBJ","AGNG","IEIH","BK4585","MEDX","SYNB","GDOC","HART","LNGR","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662973237","title":"江蘇：鼓勵商業健康保險、醫療互助等將創新藥納入保障範圍","url":"https://stock-news.laohu8.com/highlight/detail?id=2662973237","media":"金融一线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662973237?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 18:05","pubTimestamp":1787738700,"startTime":"0","endTime":"0","summary":"8月26日金融一线消息，江苏省印发《江苏省促进生物医药产业高质量发展三年行动计划》。其中提到，健全完善多元支付体系。鼓励商业健康保险、医疗互助等将创新药纳入保障范围，做优做强“江苏医惠保”等惠民商业健康保险。医保部门依托医保行业可信数据空间，对符合条件的商业健康保险给予数据融合应用、结算清分等方面的合作，相关商业健康保险保障范围内的创新药应用病例可不纳入按病种付费范围，经审核评议程序后支付。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jryx/insurance/2026-08-26/doc-iniprumn0944717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159891","MEDX","BK1161","06978","BK1574","LABU","XBI","159992","LNGR","BK4588","IBBQ","BK4585","XLV","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792595","title":"江蘇：鼓勵生物醫藥企業圍繞新產品研發、新技術應用、新業務佈局等積極增資擴產","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792595","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662792595?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 17:52","pubTimestamp":1787737951,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["399441","XBI","BK4581","BK4585","161726","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662794272","title":"江蘇：鼓勵生物醫藥企業圍繞新產品研發、新技術應用、新業務佈局等積極增資擴產","url":"https://stock-news.laohu8.com/highlight/detail?id=2662794272","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662794272?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 17:44","pubTimestamp":1787737468,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","XBI","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662260794","title":"江蘇：發揮省戰新母基金引導作用，支持生物醫藥產業專項母基金直投創新藥械項目","url":"https://stock-news.laohu8.com/highlight/detail?id=2662260794","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662260794?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 17:44","pubTimestamp":1787737443,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XBI","BK4585","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662944767","title":"江蘇：推進「人工智能+醫療健康」行動","url":"https://stock-news.laohu8.com/highlight/detail?id=2662944767","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662944767?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 17:42","pubTimestamp":1787737348,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PBOT","VHT","TECY","VUSE","GK","02834","QDEC","QQQX","NJAN","TQQQ","NOCT","LCLG","NBDS","SQQQ","NAPR","KOMP","QLD","XBI","FWD","OGIG","QMAR","NJUL","LABU","AIFD","QQQ","AQGX","MVPS","QTOC","03034","TQQY","WPAI","NEWZ","AIBU","CHAT","QQQM","TARK","QID","ARTY","IXJ","MFIG","PSQ","AGIX","CPNQ","QSWN","AIQU","GPIQ","XLV","CWC","DQJN","QQA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662941487","title":"江蘇：到2028年全省生物醫藥產業規模、創新藥械數量保持全國領先","url":"https://stock-news.laohu8.com/highlight/detail?id=2662941487","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662941487?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 17:40","pubTimestamp":1787737240,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XBI","BK4588","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159893233","title":"醫療板塊市場快訊：行業動態一覽","url":"https://stock-news.laohu8.com/highlight/detail?id=1159893233","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159893233?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 16:25","pubTimestamp":1787732717,"startTime":"0","endTime":"0","summary":"0743 GMT——花旗研究在药明合联公布上半年业绩后，基于其强劲的增长可见性，继续维持对该股的看涨立场。分析师指出，这家医疗保健服务公司的管理层重申了2026年指引，预计2025年至2030年间收入复合年增长率将达30%-35%，同时提及包括里程碑费用在内的总积压订单同比增长了62%。该行将目标价由此前的73.00港元上调至93.00港元，并维持买入评级。该股目前下跌3.6%，报77.30港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","BK4581","XLV","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662767102","title":"巴克萊(BCS.US)任命Ramin Naji為亞太區醫療健康與房地產業務主管","url":"https://stock-news.laohu8.com/highlight/detail?id=2662767102","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662767102?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 13:39","pubTimestamp":1787722750,"startTime":"0","endTime":"0","summary":"据悉，Ramin Naji将常驻香港，负责领导巴克莱在亚太地区的医疗健康及房地产板块业务，重点推动客户拓展、交易发起及执行。在汇报关系方面，Ramin Naji将在区域层面向巴克莱亚太区投资银行业务主管Avinash Thakur汇报，在职能层面则向全球医疗健康与地产业务集团主管Richard Landgarten汇报。加盟巴克莱前，Ramin Naji曾在德意志银行担任董事总经理及亚太区医疗健康业务主管。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","XLV","VHT","09979","159760","BK1148","BK4521","BK4550","BCS","XBI","BK4585","IXJ","REET","BK4588","BK4207","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662090769","title":"艾瑋得生物宣佈完成新一輪融資","url":"https://stock-news.laohu8.com/highlight/detail?id=2662090769","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662090769?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 10:32","pubTimestamp":1787711566,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","XBI","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662769800","title":"港股早評：三大指數高開，科網股普漲，生物醫藥股漲幅明顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2662769800","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662769800?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 09:37","pubTimestamp":1787708221,"startTime":"0","endTime":"0","summary":"美伊局势缓和，美股三大指数集体收涨，市场静待英伟达财报。港股三大指数集体高开，恒指涨0.49%，国指涨0.65%，恒生科技指数涨0.75%。大型科网股集体上涨，京东涨近2%，阿里巴巴、美团涨1.3%，小米、百度、腾讯涨近1%；生物医药股涨幅明显，康希诺生物大涨13%，信达生物涨6.5%，海运股、餐饮股、航空股、半导体股齐涨。另外，煤炭股、石油股普跌。(格隆汇)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260826/32347486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["161726","399441","XBI","KCAI","BK4588","BK4585","VXUS","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662476606","title":"港股生物醫藥股大漲，康希諾生物漲逾18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662476606","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662476606?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 09:37","pubTimestamp":1787708220,"startTime":"0","endTime":"0","summary":"模拟交易客户端港股生物医药股延续近期强势，康希诺生物大涨18%，信达生物绩后涨超11%，云顶新耀涨超8%，康方生物涨超6%，荣昌生物涨超5%。个股消息面上，康希诺生物宣布，子公司康希诺上海与德普世生物正式签署《mRNA个性化治疗型肿瘤疫苗共同开发战略合作框架协议》。本次合作面向全球，聚焦消化道实体瘤及罕见肿瘤治疗领域，覆盖早期研发、临床转化、注册申报及商业化等环节。目前，公司商业化产品矩阵已扩充至20款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-08-26/doc-iniprcpw5390717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["399441","BK4585","BK1191","XBI","BK4588","BK1515","VXUS","BK1161","161726","06185","BK1574","KCAI","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127147911","title":"醫療健康板塊市場綜述：市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1127147911","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127147911?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 04:52","pubTimestamp":1787691172,"startTime":"0","endTime":"0","summary":"覆盖医疗健康领域的最新市场快讯。本资讯仅通过道琼斯通讯社于美东时间4:20、12:20及16:50独家发布。分析师同时警告，市场对此反应热烈，可能源于部分交易者误将该疫苗视作预防性疗法。Moderna股价当日大涨14%，报收158.10美元，在过去一个月内市值已近乎翻了三倍。该机构将Insmed的目标价从192美元上调至195美元，理由是该公司治疗非囊性纤维化支气管扩张症的Brinsupri疗法已获日本批准。Insmed股价当日收跌1.4%，报123.98美元，今年以来已累计下跌29%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4585","LABU","XBI","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662782435","title":"派格生物醫藥-B(02565)發布中期業績 研發開支1.1億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662782435","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662782435?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 16:37","pubTimestamp":1787647040,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B 发布截至2025年6月30日止6个月中期业绩，该集团取得其他净亏损人民币1127万元，研发开支1.1亿元，每股亏损0.55元。报告期后，派达康已于多家医疗机构陆续开出首批商业化处方，进一步推进产品的临床应用及患者可及性。随着派达康首批商业化处方于全国范围内成功开出，该协议所规定的第二笔约港币4900万元权益金的所有条件已全部达成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4581","BK1161","BK4588","161726","399441","02565","XBI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}